Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs EDP 788 (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- Sponsors Enanta Pharmaceuticals
- 08 May 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 09 Oct 2014 New trial record